(2) K Raun, B S Hansen, N L Johansen, H Thgersen, et al (1998) Ipamorelin, the first selective growth hormone secretagogue European Journal of Endocrinology, 1998 Nov, Volume 139 (Issue 5), Pages 552-61
Importantly, the study confirmed that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo, with no treatment-related serious adverse events or study withdrawals occurring
Research demonstrates that both forms increase skin elasticity by 15-25% after 8-12 weeks of consistent use, though injectable therapy shows measurable improvements 2-3 weeks earlier than powder supplements
In another cellular study, miR-362-3p is shown to directly bind to and negatively regulate the expression of a disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1), which suppresses VSMCs proliferation and migration in atherosclerosis
Jul 2018;41(7):470-482